Market closed

Xencor/$XNCR

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Xencor

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

Ticker

$XNCR

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Pasadena, United States

Employees

280

Website

www.xencor.com

Xencor Metrics

BasicAdvanced

$1.4B

-

-$3.20

0.66 -

Price and volume

Market cap

$1.4B

Beta

0.66

52-week high

$26.84

52-week low

$15.31

Average daily volume

708K

Financial strength

Current ratio

6.234

Quick ratio

6.015

Long term debt to equity

10.634

Total debt to equity

12.011

Interest coverage (TTM)

-79.71%

Management effectiveness

Return on assets (TTM)

-15.24%

Return on equity (TTM)

-29.02%

Valuation

Price to revenue (TTM)

14.736

Price to book

1.96

Price to tangible book (TTM)

2.01

Price to free cash flow (TTM)

48.162

Growth

Revenue change (TTM)

-41.37%

Earnings per share change (TTM)

61.64%

3-year revenue growth (CAGR)

-19.45%

3-year earnings per share growth (CAGR)

253.83%

What the Analysts think about Xencor

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Xencor stock.

Xencor Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Xencor Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Xencor News

AllArticlesVideos

Xencor: Plamotamab NHL Data Leads To RA Program Advancement

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XNCR

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Xencor stock?

Xencor (XNCR) has a market cap of $1.4B as of January 15, 2025.

What is the P/E ratio for Xencor stock?

The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of January 15, 2025.

Does Xencor stock pay dividends?

No, Xencor (XNCR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Xencor dividend payment date?

Xencor (XNCR) stock does not pay dividends to its shareholders.

What is the beta indicator for Xencor?

Xencor (XNCR) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.